{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:52:52Z","timestamp":1789455172742,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T00:00:00Z","timestamp":1272326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In spite of significant progress in anti-HIV-1 therapy, current antiviral chemo-therapy still suffers from deleterious side effects and emerging drug resistance. Therefore, the development of novel antiviral drugs remains a crucial issue for the fight against AIDS. HIV-1 integrase is a key enzyme in the replication cycle of the retrovirus since it catalyzes the integration of the reverse transcribed viral DNA into the chromosomal DNA. Efforts to develop anti-integrase drugs started during the early nineties, culminating with the recent approval of Raltegravir. The discovery and the development of the styrylquinoline inhibitor class was an important step in the overall process. In this review we have described the key synthetic issues and the structure-activity relationship of this family of integrase inhibitors. Crystallographic and docking studies that shed light on their mechanism of action are also examined.<\/jats:p>","DOI":"10.3390\/molecules15053048","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T11:18:19Z","timestamp":1272367099000},"page":"3048-3078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors"],"prefix":"10.3390","volume":"15","author":[{"given":"Jean-Fran\u00e7ois","family":"Mouscadet","sequence":"first","affiliation":[{"name":"LBPA, CNRS, Ecole Normale Sup\u00e9rieure de Cachan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Desma\u00eble","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Paris-Sud, UMR CNRS 8076 BIOCIS, Ch\u00e2tenay-Malabry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/095632020901900502","article-title":"Novel compounds for the treatment of HIV type-1 infection","volume":"19","author":"Stellbrink","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1592\/phco.29.3.295","article-title":"Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1","volume":"29","author":"Hunt","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitor to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nature Rev. Drug Disc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0065-2660(05)55005-3","article-title":"Retroviral DNA integration-mechanism and consequences","volume":"55","author":"Lewinski","year":"2005","journal-title":"Adv. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1517\/14656560902911488","article-title":"Treatment of HIV infection with raltegravir","volume":"10","author":"Chirch","year":"2009","journal-title":"Expert Opin. Pharmaco."},{"key":"ref_7","first-page":"203","article-title":"GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection","volume":"11","author":"Vandeckerckhove","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/TCRM.S3137","article-title":"Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection","volume":"5","author":"Katlama","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20865","DOI":"10.1073\/pnas.0908074106","article-title":"Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir","volume":"106","author":"Eilat","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/ar9500877","article-title":"Structure and nuclease activity of simple dinuclear metal complexes: Quantitative dissection of the role of metal ions","volume":"32","author":"Williams","year":"1999","journal-title":"Acc. Chem. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/j.1460-2075.1991.tb07917.x","article-title":"Structural basis for the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism","volume":"10","author":"Beese","year":"1991","journal-title":"EMBO J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.95.16.9150","article-title":"Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium","volume":"95","author":"Goldgur","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0163-7258(99)00059-5","article-title":"Investigations on human immunodeficiency virus type 1 integrase\/DNA binding interactions via molecular dynamics and electrostatics calculations","volume":"85","author":"Lins","year":"2000","journal-title":"Pharmacol. Therapeut."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1021\/jm980043e","article-title":"Styrylquinoline derivatives: a new class of potent HIV-1-integrase inhibitors that block HIV-1 replication in CEM cells","volume":"41","author":"Mekouar","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/je60042a005","article-title":"Carboxylation of substituted phenol in N,N-dimethylamide solvents at atmospheric pressure","volume":"14","author":"Meek","year":"1969","journal-title":"J. Chem. Eng. Data"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.1021\/ja00143a021","article-title":"O-TRENSOX: A promising water-soluble iron chelator (Both FeIII and FeII) potentally suitable for plant nutrition and iron chelation therapy","volume":"117","author":"Baret","year":"1995","journal-title":"J. Am. Chem. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1081\/SCC-200046532","article-title":"A simple and effective method for chemoselective esterification of phenolic acids","volume":"35","author":"Guo","year":"2005","journal-title":"Synth. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.bmcl.2004.03.005","article-title":"Linker-Modified Quinoline Derivatives Targeting HIV-1 Integrase: Synthesis and Biological Activity","volume":"14","author":"Zouhiri","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_19","unstructured":"Desma\u00eble, D., and Zouhiri, F. Unpublished Results."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157018007779422532","article-title":"Fragment based approach for the investigation of HIV-1 integrase inhibition","volume":"4","author":"Polanski","year":"2007","journal-title":"Lett. Drug Des. Discovery"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/157018006776286934","article-title":"5-hydroxy-6-quinaldic acid as a novel molecular scaffold for HIV-1 integrase inhibitors","volume":"3","author":"Polanski","year":"2006","journal-title":"Lett. Drug Des. Discovery"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/jm025553u","article-title":"Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells","volume":"46","author":"Zhuang","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.bmcl.2006.03.003","article-title":"A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors","volume":"16","author":"Guare","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/1521-4184(200208)335:6<277::AID-ARDP277>3.0.CO;2-A","article-title":"Styrylquinazoline derivatives as HIV-1 integrase inhibitors","volume":"335","author":"Lee","year":"2002","journal-title":"Arch. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1021\/jm020845g","article-title":"Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines","volume":"45","author":"Polanski","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/jm990467o","article-title":"Structure-activity relationships and binding mode of Styrylquinolines as potent inhibitors of HIV-1-integrase and replication of HIV-1 in cell culture","volume":"43","author":"Zouhiri","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.farmac.2003.08.001","article-title":"Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitors","volume":"58","author":"Yoo","year":"2003","journal-title":"Farmaco"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/jo01282a063","article-title":"The ortho bromination of phenols","volume":"32","author":"Pearson","year":"1967","journal-title":"J. Org. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/S0040-4039(00)00268-9","article-title":"2-Benzyloxymethyl-5-(tributylstannyl)tetrazole. A reagent for the preparation of 5-aryl- and 5-heteroaryl-1H-tetrazoles via the Stille reaction","volume":"41","author":"Bookser","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"ref_30","unstructured":"Normand-Bayle, M. Synth\u00e8se et activit\u00e9 biologique de nouvelles styrylquinol\u00e9ines inhibitrices de l\u2019int\u00e9grase du VIH-1. Ph.D. Dissertation, Universit\u00e9 Paris-Sud : Paris, France, 2007."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Espeseth, A.S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J.Y., Young, S., Hamill, T., Cole, J.L., and Hazuda, D.J. (2000). Proc. Natl. Acad. Sci. USA, 97, 11244\u201311249.","DOI":"10.1073\/pnas.200139397"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1016\/S0040-4039(01)01767-1","article-title":"HIV-1 replication inhibitors of the styrylquinoline class: incorporation of a masked diketo acid pharmacophore","volume":"42","author":"Zouhiri","year":"2001","journal-title":"Tetrahedron Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1016\/j.bmcl.2005.06.036","article-title":"New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl\/acyl groups at the C-7 position: Synthesis and biological activity","volume":"15","author":"Zouhiri","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.tetlet.2005.02.033","article-title":"HIV-1 replication inhibitors of the styrylquinoline class: Introduction of an additional carboxyl group at the C-5 position of the quinoline","volume":"46","author":"Zouhiri","year":"2005","journal-title":"Tetrahedron Lett."},{"key":"ref_35","unstructured":"Michaut, M., Monneret, C., Soma, E., Thibault, L., and Wermuth, C. (2010). Styrylquinolines, their process of preparartion and their therapeutic uses. (WO\/2010\/010148 A1), PCT Int. Appl."},{"key":"ref_36","first-page":"1105","article-title":"Design and synthesis of 2-styrylquinoline-7-sulfonamide derivatives as potential HIV integrase inhibitors","volume":"29","author":"Zeng","year":"2009","journal-title":"Chin. J. Org. Chem."},{"key":"ref_37","unstructured":"Auclair, C., Giethlen, B., Michaut, M., Monneret, C., Soma, E., Thibault, L., and Wermuth, C. (2010). Styrylquinolines, their process of preparartion and their therapeutic uses. (WO\/2010\/010147 A1), PCT Int. Appl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1126\/science.1738845","article-title":"Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus","volume":"255","author":"Chow","year":"1992","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1021\/jp0687551","article-title":"Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors","volume":"B111","author":"Courcot","year":"2007","journal-title":"J. Phys. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1021\/jm9911581","article-title":"Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives","volume":"43","author":"Ouali","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18388\/abp.2000_4058","article-title":"Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core","volume":"47","author":"Ouali","year":"2000","journal-title":"Acta Biochim. Pol."},{"key":"ref_42","first-page":"950","article-title":"Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis docking studies","volume":"25","author":"Ma","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/jp0582179","article-title":"Experimental\/theoretical electrostatic properties of a styrylquinoline-type HIV-1 integrase inhibitor and its progenitors","volume":"110","author":"Firley","year":"2006","journal-title":"J. Phys. Chem. B"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/mol.65.1.85","article-title":"Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro","volume":"65","author":"Deprez","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1093\/emboj\/16.22.6849","article-title":"Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking","volume":"16","author":"Jenkins","year":"1997","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1093\/emboj\/17.19.5832","article-title":"Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction","volume":"17","author":"Esposito","year":"1998","journal-title":"EMBO J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1128\/JVI.75.16.7756-7762.2001","article-title":"Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection","volume":"75","author":"Harper","year":"2001","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1021\/jm025554m","article-title":"AutoDocking dinucleotides to the HIV-1 integrase core domain: exploring possible binding sites for viral and genomic DNA","volume":"45","author":"Perryman","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/JVI.78.11.5728-5736.2004","article-title":"Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents","volume":"78","author":"Bonnenfant","year":"2004","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1124\/mol.104.001735","article-title":"Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives","volume":"66","author":"Mousnier","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/AAC.01075-09","article-title":"Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo","volume":"54","author":"Delelis","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1128\/JVI.76.23.12087-12096.2002","article-title":"Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import","volume":"76","author":"Dvorin","year":"2002","journal-title":"J. Virol."},{"key":"ref_55","first-page":"A29","article-title":"New integrase binding inhibitors acting in synergy with raltegravir","volume":"14","author":"Thibault","year":"2009","journal-title":"Antivir. Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/15\/5\/3048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:02:16Z","timestamp":1760220136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/15\/5\/3048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,27]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,5]]}},"alternative-id":["15053048"],"URL":"https:\/\/doi.org\/10.3390\/molecules15053048","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,27]]}}}